XOMA : Analysis & Opinions

  1. Xoma Phase 2 Pediatric Trial Wins UK Nod (XOMA)

    October 20, 2016
    Xoma received preliminary approval to initiate a Phase 2 clinical study of its Xoma 358 drug to treat children over age 2 ...
  2. Xoma Sets 1-for-20 Reverse Stock Split (XOMA)

    October 17, 2016
    Xoma declared a 1-for-20 reverse stock split to comply with the $1 per share minimum bid price required for continued listing ...
  3. XOMA Reports Success in Insulin Trials (XOMA)

    September 16, 2016
    XOMA’s 358 trial success indicates its lead in offering the therapy for widespread insulin-related abnormalities.